Frankfurt am Main — Baker McKenzie advised Chr. Hansen Holding A/S (Chr. Hansen) in connection with the acquisition of all shares in Jennewein Biotechnologie GmbH (Jennewein), a leading company in the market for human milk oligosaccharides (HMOs). The purchase price amounts to approximately EUR 310 million (on a debt-free basis). The transaction is expected to close before the end of September 2020.
Following the acquisition, Chr. Hansen plans to invest more than EUR 200 million by 2025, including in a new production facility. This is intended to expand HMO capacity to meet anticipated demand.
Jennewein is a leading international biotechnology company with a range of products in the field of human milk oligosaccharides (HMOs) and rare monosaccharides such as L‑fucose and sialic acid. Jennewein produces a broad portfolio of innovative HMO products, including 2′-fucosyllactose, 3′-fucosyllactose, lacto-N-neotetraose, and lacto-Ntetraose. These are rare sugars used in the food industry (especially in infant milk formula), in the pharmaceutical industry and in the cosmetics industry.
Chr. Hansen is a leading global life science company developing products based on natural ingredients for the food, nutrition, pharmaceutical and agricultural industries. This includes the development and production of cultures, enzymes, probiotics and natural colors for a variety of foods, confectionery, beverages, dietary supplements as well as animal feed and crop protection products. This allows food manufacturers, for example, to reduce the use of chemicals and other artificial substitutes, thus creating “more” from “less,” which is what makes the food products in question special in today’s world. In 2019, Chr. Hansen was ranked the most sustainable company in the world by Corporate Knights.
Advisor Chr. Hansen Holding A/S: Baker McKenzie
Lead Corporate/M&A: Christian Atzler, Foto (Partner, Frankfurt)
Team: Corporate/M&A: Dr. Peter Wand (Partner, Frankfurt), Dr. Markus Mörtel (Senior Associate, Frankfurt), Jessica Köhler (Associate, Frankfurt), Rouven Reuter (Associate, Frankfurt), Esther Xiang (Associate, Frankfurt)
Commercial: Dr. Johannes Teichmann (Partner, Frankfurt), Dr. Ingmar Oltmanns (Associate, Frankfurt) Rebecca Romig, Isabel Weaver (both Associates, Frankfurt)
IP: Dr. Rembert Niebel (Partner, Frankfurt), Alexander Ritter (Senior Associate, Munich), Lena Weber (Associate, Frankfurt)
IT: Dr. Holger Lutz (Partner, Frankfurt), Dr. Tobias Born (Senior Associate, Frankfurt)
Regulatory: Dr. Frank Pflüger (Partner, Frankfurt), Dr. Christian Lebrecht (Associate, Frankfurt)
Employment: Dr. Christian Reichel (Partner, Frankfurt), Dr. Felix Diehl (Associate, Frankfurt)
Real Estate: Dr. Florian Thamm (Partner, Frankfurt), Till Pflug (Associate, Frankfurt)
Banking & Finance: Dr. Oliver Socher (Partner, Frankfurt), Silke Fritz (Counsel, Frankfurt), Philipp Thimm (Associate, Frankfurt)
Foreign Trade Law: Anahita Thoms (Partner, Düsseldorf), Alexander Ehrle (Associate, Berlin)
Antitrust: Gavin Bushell (Partner, Brussels), Christian Horstkotte (Partner, Düsseldorf)
Inhouse Legal Chr. Hansen: Christel May-Worre (Hørsholm, Denmark)
About Baker McKenzie
Baker McKenzie’s global Corporate/M&A team advises on more cross-border transactions than any other law firm. Most recently, Baker McKenzie advised GEA on the sale of compressor manufacturer Bock to NORD, DBAG on an investment in congatec Holding AG, benpac holding ag on the acquisition of Gallus Group, SAP on the sale of the SAP Digital Interconnect communications unit to Sinch AB, Paragon Partners on the acquisition of Castolin Eutectic, Air Liquide on the sale of the Schülke Group to Swedish financial investor EQT, METRO AG on the sale of its China business and the establishment of a strategic partnership with Wumei, Bayer AG on the sale of its majority stake in chemical park operator Currenta, SPIE on the acquisition of OSMO, Toppan Printing Co. Ltd. on its acquisition of the German Interprint Group, and Evonik on the sale of its methacrylates group to Advent International.